Brokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.17

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.17.

Several brokerages have recently weighed in on SGMO. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an "overweight" rating in a research note on Thursday, November 14th. Jefferies Financial Group decreased their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating for the company in a research note on Tuesday, December 31st. StockNews.com cut Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 24th. Finally, Truist Financial decreased their price target on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SGMO. Vontobel Holding Ltd. increased its position in shares of Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company's stock valued at $259,000 after acquiring an additional 241,440 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 38,850 shares during the last quarter. Golden State Equity Partners increased its position in Sangamo Therapeutics by 35.2% in the third quarter. Golden State Equity Partners now owns 266,484 shares of the biopharmaceutical company's stock worth $231,000 after buying an additional 69,368 shares during the last quarter. Meritage Portfolio Management increased its position in Sangamo Therapeutics by 8.6% in the third quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 6,740 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company's stock worth $956,000 after buying an additional 57,125 shares during the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock traded down $0.05 during trading on Wednesday, reaching $1.07. 4,272,715 shares of the company's stock were exchanged, compared to its average volume of 4,993,464. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18. The firm's 50-day moving average price is $1.47 and its 200 day moving average price is $1.39. The company has a market cap of $223.26 million, a P/E ratio of -1.43 and a beta of 1.30.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.